3 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
Follow E10030 aptamer: new trials by email Literature Review of E10030 aptamer trials Research Report on E10030 aptamer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 645 | 2014-05-01 | 2024-10-31 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 627 | 2013-08-01 | 2024-10-30 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 619 | 2013-08-01 | 2024-10-30 |
Choroidal Neovascularization (3) · Macular Degeneration (3)
United States (3) · Argentina (2) · Australia (2) · Austria (2) · Brazil (2) · Canada (2) · Colombia (2) · Czechia (2) · Estonia (2) · France (2) · Germany (2) · Hungary (2) · Israel (2) · Italy (2) · Latvia (2)